Viewing nowEnpirin Capsule 75 mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Albozen Korea Co., Ltd.

MFDS item code 201109222 · Approved 2011.10.27 · Insurance code 652603050
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures in epilepsy
This medication effectively treats peripheral and central neuropathic pain in adults. It is also used as an adjunct for partial seizures whether or not there are secondary generalized symptoms in patients with epilepsy. Furthermore, it helps alleviate symptoms in patients with fibromyalgia. It is used to contribute to the management of pain and seizures associated with major neurological disorders and improve the quality of life for patients.
Administer this medicine orally as pregabalin in 2 divided doses per day, with or without food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function (see section 5, “Patients with renal impairment”). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section 4, “Discontinuation”). 2. Epilepsy Adults: The starting dose is 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, it may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) | Starting dose (mg/day) | Maximum dose (mg/day) | Dosing regimen ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be given after each 4-hour hemodialysis session. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: Supplemental dose refers to an additional dose given once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors, so mood or behavior changes must be closely monitored during treatment. Patients with allergies to pregabalin or any component of this medication, or those with certain genetic lactose-related disorders, should not take this medication. Diabetic patients should be cautious as weight gain may necessitate dosage adjustments of blood sugar control medications. If symptoms of angioedema occur, discontinue the medication immediately and consult with a healthcare professional. Older adults should be especially careful during initial treatment due to the increased risk of falls from side effects such as dizziness and drowsiness. Blurry vision or changes in vision may occur; these symptoms may improve after discontinuation of the medication. Suddenly stopping this medication after long-term use may lead to withdrawal symptoms such as insomnia, headache, and anxiety. Patients with a history of substance abuse should be careful with potential misuse or dependence on this medication. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should also use caution when taking this medication. There is a risk of central nervous system depression when taken with opioid analgesics, so caution is advised. Patients with respiratory diseases, kidney disorders, or the elderly are at risk of severe respiratory depression, necessitating potential dosage adjustments. In early pregnancy, there may be a risk of fetal malformation, so use should be avoided, and women of childbearing potential should use effective contraception. Lactating women should consult their physician as this medication may be passed into breast milk, and nursing should be discontinued. When engaging in hazardous activities such as driving or operating machinery, caution is needed due to dizziness and drowsiness. Severe skin reactions may occur; monitor skin condition carefully and discontinue immediately if abnormalities arise. In cases of overdose, symptoms such as drowsiness, confusion, and depression may occur, and treatments such as blood dialysis may be required if necessary. Special caution is needed for children, the elderly, and patients with impaired kidney function, and storage should be out of reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from exposure to air or moisture, at a temperature between 15 to 30 degrees Celsius. Storing in this manner will help maintain the effectiveness of the medication for a longer period.
A hard capsule with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow in color.
30 capsules/bottle, 200 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Albozen Korea Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.